Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference Nov 10, 2015
Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey Oct 20, 2015
Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases Sep 25, 2015
Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 ‘apabetalone’ a Selective BET Inhibitor Sep 1, 2015
International Clinical Steering Committee Announced for Resverlogix’s Phase 3 BETonMACE Clinical Trial with RVX-208 “apabetalone” Aug 5, 2015
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink Jul 9, 2015
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association’s (ADA) Scientific Sessions in Boston, MA Jun 9, 2015
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement Apr 28, 2015
